TGW-211

N/A

Report date: 2025/09/15 11:01:13

Base Information

Drug NameTGW-211

Drug Alias NameRIT: trastuzumab-TCO-DOTATGW-211TRG001TRG-001

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionIonising radiation emittersReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTagworks Pharmaceuticals BV

China Registration ClassN/A

Develop Information

Active CompaniesTagworks Pharmaceuticals BV

Inactive CompaniesN/A

Active IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A